Lisinopril dihydrate: Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate, a lysine analogue of MK 421, is a long-acting and highly selective ACE inhibitor with an IC50 of 4.7 nM, making it a benchmark tool in hypertension, heart failure, and renal research (Tieku & Hooper 1992). It acts by blocking the conversion of angiotensin I to angiotensin II, leading to reduced plasma angiotensin II and aldosterone, increased renin, and sustained blood pressure reduction (ApexBio B3290). The compound is water-soluble (≥2.46 mg/mL with warming/ultrasound), has a molecular weight of 441.52 g/mol, and a purity of 98% by mass spectrometry and NMR. Lisinopril dihydrate is especially valuable in translational models due to its high specificity, robust validation, and compatibility with a range of experimental workflows (Related Article). Proper storage conditions are essential for reproducibility.

Biological Rationale

Lisinopril dihydrate is designed to inhibit the angiotensin converting enzyme (ACE; EC 3.4.15.1), a zinc metallopeptidase responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor. The renin-angiotensin system (RAS) is a key pathway in blood pressure regulation and fluid balance (Tieku & Hooper 1992). Increased activity of ACE elevates angiotensin II, resulting in vasoconstriction, sodium retention, and hypertension. By selectively blocking ACE, lisinopril dihydrate reduces angiotensin II and aldosterone levels, leading to vasodilation and natriuresis. The biological effects are well-characterized in both animal models and clinical studies, supporting its use in research on hypertension, heart failure, myocardial infarction, and diabetic nephropathy (See also—this article extends the foundational rationale by detailing verifiable molecular benchmarks).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate inhibits ACE by binding to its active site, preventing the hydrolysis of angiotensin I to angiotensin II. The compound is a non-sulfhydryl lysine analogue that achieves high affinity via chelation of the enzyme’s zinc atom and hydrogen bonding. This inhibition leads to a decrease in vasoconstrictive angiotensin II and aldosterone synthesis and an increase in plasma renin activity. The molecular action is highly specific, with minimal off-target activity on related aminopeptidases (AP-A, AP-N, AP-W) at concentrations used for ACE inhibition (Tieku & Hooper 1992). This selectivity distinguishes lisinopril dihydrate from older, less selective ACE inhibitors, reducing confounding effects in RAS-focused studies. Quantitatively, the IC50 for ACE inhibition is 4.7 nM in vitro (ApexBio B3290).

Evidence & Benchmarks

• Lisinopril dihydrate achieves >98% purity, confirmed by mass spectrometry and NMR (ApexBio B3290, product page).
• The IC50 for ACE inhibition is 4.7 nM under standard assay conditions (phosphate buffer pH 8.3, 37°C, 30 min) (Tieku & Hooper 1992).
• Lisinopril dihydrate is water-soluble at concentrations ≥2.46 mg/mL with gentle warming and ultrasonic treatment (ApexBio B3290, product page).
• In comparative inhibition studies, lisinopril and other carboxyalkyl ACE inhibitors show negligible inhibition of aminopeptidase A, N, or W at up to 100 μM, confirming target specificity (Tieku & Hooper 1992).
• Validated for use in preclinical models of hypertension, heart failure, myocardial infarction, and diabetic nephropathy (Related Article—this article clarifies detailed protocol integration).

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely used in basic and translational research targeting the renin-angiotensin system. Its principal applications include:

• Modeling hypertension and testing novel antihypertensive interventions.
• Investigating heart failure mechanisms and therapies.
• Studying acute myocardial infarction and post-infarct remodeling.
• Evaluating diabetic nephropathy and renal protective strategies.

Lisinopril dihydrate’s high selectivity and water solubility allow for flexible dosing and reproducible delivery in cell, tissue, and animal models. When compared to other ACE inhibitors, its non-sulfhydryl structure minimizes off-target activity and side effects (Related Article—this article updates selectivity and workflow parameters).

Common Pitfalls or Misconceptions

• Not a pan-zinc metallopeptidase inhibitor: Lisinopril dihydrate does not inhibit aminopeptidase A, N, or W at pharmacological concentrations (Tieku & Hooper 1992).
• Not effective for peptide substrates unrelated to ACE: It lacks activity on endopeptidase-24.11 or dipeptidyl peptidases (Tieku & Hooper 1992).
• Not interchangeable with sulfhydryl ACE inhibitors: Lisinopril’s non-sulfhydryl structure confers different side effect and selectivity profiles compared to captopril or zofenoprilat.
• Not stable in solution for long-term storage: Freshly prepared solutions are recommended; avoid long-term storage of aqueous stocks (ApexBio B3290).
• Not suitable for ethanol-based formulations: Compound is insoluble in ethanol (ApexBio B3290).

Workflow Integration & Parameters

Lisinopril dihydrate is supplied as a solid, molecular weight 441.52 g/mol, chemical formula C21H35N3O7. For dissolution, add water to achieve ≥2.46 mg/mL, using gentle warming (≤37°C) and ultrasonic treatment if needed. Sterile filtration is recommended for cell culture applications. Store dry powder desiccated at room temperature; avoid repeated freeze-thaw cycles or long-term solution storage. For in vivo studies, dosing regimens should be guided by pharmacokinetic data specific to the model organism (Related Article—this article extends guidance on experimental design).

Shipping is on blue ice for small molecules. Quality is confirmed by mass spectrometry and NMR; each batch includes a certificate of analysis (purity ≥98%).

Conclusion & Outlook

Lisinopril dihydrate remains a reference ACE inhibitor for research on the renin-angiotensin system and related pathologies. Its high selectivity, potency, and solubility support robust, reproducible results in preclinical studies. As experimental models evolve, the compound’s validated benchmarks and clear workflow parameters ensure its enduring value. For further mechanistic and strategic insight, see this discussion—this article clarifies NMR validation and extends mechanism-of-action analysis.

For product details and ordering, visit the Lisinopril dihydrate product page (B3290).